Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction

Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure

(2016) Abhishek S. Chitnis et al.   American Journal of Alzheimers Disease and Other Dementias

The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects

(2016) Thomas H. Langenickel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure

(2016) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence of Dementia over Three Decades in the Framingham Heart Study

(2016) Claudia L. Satizabal et al.   NEW ENGLAND JOURNAL OF MEDICINE

A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II

(2016) F. E. Matthews et al.   Nature Communications

An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer’s disease

(2016) Abdel G. Elkahloun et al.   Alzheimers Research & Therapy

Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease

(2015) Robert Baranello et al.   Current Alzheimer Research

Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances

(2015) John J.V. McMurray   EUROPEAN JOURNAL OF HEART FAILURE

The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics

(2015) Henry Krum et al.   EUROPEAN JOURNAL OF HEART FAILURE

‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure

(2015) Jane A Cannon et al.   Alzheimers Research & Therapy

Treatment of vascular risk factors in patients with a diagnosis of Alzheimer’s disease: a systematic review

(2014) Raffaella Valenti et al.   BMC Medicine

Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

(2014) John J. V. McMurray et al.   EUROPEAN JOURNAL OF HEART FAILURE

The dark sides of amyloid in Alzheimer's disease pathogenesis

(2014) Pierpaolo Sorrentino et al.   FEBS LETTERS

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer’s disease

(2014) Natalia N. Nalivaeva et al.   Frontiers in Aging Neuroscience

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact

(2013) John J. V. McMurray et al.   EUROPEAN JOURNAL OF HEART FAILURE

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

(2013) Jean-Charles Lambert et al.   NATURE GENETICS

Long-Term Cognitive Impairment after Critical Illness

(2013) P.P. Pandharipande et al.   NEW ENGLAND JOURNAL OF MEDICINE